Analysis: Mounting Pressure on China About Covid 鈥楲ab Leak鈥 Could Backfire
Where the coronavirus originated remains a mystery and the Chinese are bucking demands to let investigators see more.
Showing 101 - 119 of 119
-
-
To the Bat Cave: In 吃瓜不打烊 of Covid鈥檚 Origins, Scientists Reignite Polarizing Debate on Wuhan 鈥楲ab Leak鈥
Leading virologists, including Dr. Anthony Fauci, are demanding a deeper probe into China鈥檚 Wuhan Institute of Virology as they try to identify the source of the deadly coronavirus.
By Arthur Allen -
This Small Canadian Drugmaker Wants to Make J&J Vaccines for Poor Nations. It Needs More Than a Patent Waiver.
All agree that covid vaccines are urgently needed to stop the pandemic, but simply waiving patents fails to provide technological know-how and address supply chain challenges.
By Sarah Jane Tribble and Arthur Allen -
You Don鈥檛 Have to Suffer to Benefit From Covid Vaccination 鈥 But Some Prefer It
In the times of smallpox, vaccination was accompanied by blood, sweat, fire and brimstone. Nowadays, a slight fever may make you feel as if you鈥檝e earned the reward of immunity from covid. But you鈥檙e protected even without a nasty reaction to the vaccine.
By Arthur Allen -
The Case for Donating US Covid Vaccines Overseas
For now, there鈥檚 not enough vaccine for the U.S., but that could change within a few months. Vaccinating other nations will be key to stopping the pandemic 鈥 and keeping it away from our shores.
By Arthur Allen -
鈥楨xplained by KHN鈥: Consumer Concerns About the Covid Vaccines
Our newsroom has some of the best and smartest health care and health policy reporters in the business. We鈥檝e created a new video series 鈥 鈥淓xplained by KHN鈥 鈥 in which our correspondents and editors answer common health care and policy questions. In this edition we cover consumer concerns over the covid-19 vaccines.
-
To Extract More Doses per Vial, Vaccinators Put Squeeze on FDA to Relax Vaccine Handling Advice
Although vaccine supply is ramping up, the supply gap puts pressure on vaccinating teams to extract every drop they can. Some are asking the FDA to waive guidance against extracting vaccine from two vials with the same needle. It鈥檚 worth a shot.
By Arthur Allen -
After Billions of Dollars and Dozens of Wartime Declarations, Why Are Vaccines Still in Short Supply?
The Trump and Biden administrations both imposed wartime production requirements. But industry experts say the vast quantities of raw materials and specialty equipment needed for billions of newfangled vaccines have required herculean logistical efforts.
By Rachana Pradhan and Arthur Allen -
When Your Chance for a Covid Shot Comes, Don鈥檛 Worry About the Numbers
The Johnson & Johnson vaccine that the FDA cleared Saturday was 66% effective overall in preventing moderate to severe covid, while the Pfizer and Moderna vaccines were more than 90% effective. But the numbers aren鈥檛 exactly comparable. And all three shots prevent hospitalization and death.
By Arthur Allen and Liz Szabo -
Why Even Presidential Pressure Might Not Get More Vaccine to Market Faster
Even invoking the widely heralded Defense Production Act to pressure drugmakers wouldn鈥檛 overcome vast obstacles.
-
Commentary
Eureka! Two Vaccines Work 鈥 But What About the Also-Rans in the Pharma Arms Race?
How two effective vaccines on the market make it so much harder to quickly test any competing vaccines.
By Arthur Allen -
Pediatricians Want Kids to Be Part of COVID Vaccine Trials
Some years from now, infants and school-aged children will probably be the mainstay of a universal vaccination program against COVID-19 in the United States. But first, doctors want to be sure that newfangled vaccines won鈥檛 harm them.
By Arthur Allen -
Government-Funded Scientists Laid the Groundwork for Billion-Dollar Vaccines
Drugmakers will walk away with massive profits, but much of the pioneering work on mRNA vaccines was done with government money.
By Arthur Allen -
Five Important Questions About Pfizer鈥檚 COVID-19 Vaccine
The drugmaker says its mRNA vaccine worked in 90% of patients in its trial, but some observers question how long immunity will last and who will benefit.
By Arthur Allen -
NIH ‘Very Concerned’ About Serious Side Effect in Coronavirus Vaccine Trial
The AstraZeneca trial is on hold in the U.S. as scientists try to unravel whether a rare neurological condition is linked to the vaccine. But regulators are frustrated by a lack of information from the drugmaker.
By Arthur Allen and Liz Szabo -
LA Hospital Seeks Vaccine Trial Participants Among Its Own High-Risk Patients
Harbor-UCLA Medical Center serves patients who are especially vulnerable to the coronavirus: They are essential workers, have chronic diseases and are members of underrepresented racial and ethnic groups. When the safety-net hospital kicks off enrollment for its COVID-19 vaccine trial Wednesday, it will look to those patients to participate.
By Arthur Allen -
Trust, Fear and Solidarity Will Determine the Success of a COVID Vaccine
Polio terrified Americans, and in 1955, when Jonas Salk鈥檚 vaccine became available, they snapped it up like candy. Sixty-five years later, COVID is the latest dread virus, but many undercurrents could inhibit its acceptance.
By Arthur Allen -
Public Health Experts Fear a Hasty FDA Signoff on Vaccine
The FDA must approve any coronavirus vaccine before it鈥檚 widely distributed, but political pressure could cloud the decision.
By Arthur Allen -
Analysis: Get Ready For The Vaccine 鈥 They鈥檙e Never Simple
Trials are an immense undertaking involving tens of thousands of participants. They鈥檙e likely to start this summer 鈥 but don鈥檛 expect quick results. And what鈥檚 a successful result, anyway?
By Arthur Allen
Sign Up For Our Newsletter
Stay informed by signing up for the Morning Briefing and other emails: